University of Washington clinical trial pipeline

18 trials changed in the last 30 days: 1 stopped, 11 with notable changes, 6 with minor changes only.

1. Stopped

   Etoposide, Prednisone, Vincristine, Cyclophosphamide, and…Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) · Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

   Recruitment suspended

   Sponsor's reason: Safety Review

   University of Washington·Phase 2· NCT06738368· Registry history of NCT06738368 on ClinicalTrials.gov (opens the registry)

   Updated Sep 29, 2026

2. Notable

   Decitabine With Ruxolitinib, Fedratinib or Pacritinib…Decitabine With Ruxolitinib, Fedratinib or Pacritinib · Accelerated/Blast Phase Myeloproliferative Neoplasms

   Primary and study completion pushed from Nov 11, 2026 to Nov 11, 2027

   University of Washington·Phase 2· NCT04282187· Registry history of NCT04282187 on ClinicalTrials.gov (opens the registry)

   Updated Sep 17, 2026

3. Notable

   GAIN · Improving HIV Diagnosis, Linkage to Care, and Prevention…GAIN · Improving HIV Diagnosis, Linkage to Care, and Prevention Services With HIV Point-of-Care Nucleic Acid Tests

   Primary endpoint(s) modified

   Also in this update: Primary completion date changed from estimate of Aug 31, 2024 to Dec 23, 2025; Results posted: Sep 17, 2026

   University of Washington·Not applicable· NCT04880200· Registry history of NCT04880200 on ClinicalTrials.gov (opens the registry)

   Updated Sep 17, 2026

4. Notable

   Polatuzumab Vedotin and Combination Chemotherapy With or Without…Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab · Untreated Aggressive Large B-cell Lymphoma

   Phase changed: Phase 1 → Phase 1/2

   And 1 more change in the last 30 days

   University of Washington·Phase 1/2· NCT04231877· Registry history of NCT04231877 on ClinicalTrials.gov (opens the registry)

   Updated Oct 2, 2026

5. Notable

   INTERACT · Inherited and Environmental Risks Acting on Body…INTERACT · Inherited and Environmental Risks Acting on Body Weight

   Enrolling by invitation only

   University of Washington·Not applicable· NCT07430852· Registry history of NCT07430852 on ClinicalTrials.gov (opens the registry)

   Updated Oct 2, 2026

6. Notable

   [18F]FTT Positron Emission Tomography/Computed Tomography to…[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma

   Recruitment opened

   University of Washington·Phase 2· NCT07673341· Registry history of NCT07673341 on ClinicalTrials.gov (opens the registry)

   Updated Sep 25, 2026

7. Notable

   Uterine Lavage to Detect Ovarian Cancer Risk

   Recruitment opened

   Also in this update: Start date changed from estimate of Oct 1, 2026 to Sep 3, 2026

   University of Washington·Not applicable· NCT07772869· Registry history of NCT07772869 on ClinicalTrials.gov (opens the registry)

   Updated Sep 14, 2026

8. Notable

   D3 · Decisions During Drinking

   Results posted: Oct 8, 2026

   University of Washington·Not applicable· NCT06978140· Registry history of NCT06978140 on ClinicalTrials.gov (opens the registry)

   Updated Oct 8, 2026

9. Notable

   Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral…Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

   Results posted: Sep 16, 2026

   University of Washington·Phase 1/2· NCT05316688· Registry history of NCT05316688 on ClinicalTrials.gov (opens the registry)

   Updated Sep 16, 2026

10. Notable

    Comprehensive Self-Management Intervention · Inflammatory Bowel…Comprehensive Self-Management Intervention · Inflammatory Bowel Disease

    Results posted: Sep 28, 2026

    University of Washington·Not applicable· NCT05651542· Registry history of NCT05651542 on ClinicalTrials.gov (opens the registry)

    Updated Sep 28, 2026

11. Notable

    EC-PC · Cancer Parenting Program for the Enhancement of the…EC-PC · Cancer Parenting Program for the Enhancement of the Quality of Life · Advanced Cancer and Their Children

    Results posted: Sep 22, 2026

    University of Washington·Not applicable· NCT05477784· Registry history of NCT05477784 on ClinicalTrials.gov (opens the registry)

    Updated Sep 22, 2026

12. Notable

    Spinal Stimulation and Mobility Devices

    Results posted: Sep 18, 2026

    Also in this update: Trial completed; Final enrollment: 10 participants (planned 20)

    University of Washington·Not applicable· NCT05520359· Registry history of NCT05520359 on ClinicalTrials.gov (opens the registry)

    Updated Sep 18, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.